Breast Cancer :: FDA recommends Evista use to reduce breast cancer risk in postmenopausal women

Eli Lilly and Company (NYSE: LLY) announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to recommend approval of its osteoporosis drug EVISTA(R) (raloxifene HCl) for a new use to reduce invasive breast cancer risk in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.

Breast Cancer :: Fruit, vegetables does not reduce breast cancer recurrence

Women with early stage breast cancer who adopted a diet very high in vegetables, fruit and fiber and low in fat did not have a lower risk of breast cancer recurrence compared to women who followed a diet of five or more servings a day of fruit and vegetables (the ?5-A-Day? diet), according to a study in the July 18 issue of JAMA.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack